Tobias Walbert MD

Neurology•Detroit, MI

Neurooncology, Hospice and Palliative Medicine

Associate Professor, Neurology, Wayne State University SOM

Join to View Full Profile

2799 W. Grand BoulevardDetroit, MI 48202
Phone+1 313-916-2723

Education & Training

University of Texas M D Anderson Cancer CenterFellowship, Neuro-Oncology, 2008 - 2010
Case Western Reserve University/University Hospitals Cleveland Medical CenterResidency, Neurology, 2005 - 2008
Case Western Reserve University/University Hospitals Cleveland Medical CenterInternship, Internal Medicine, 2004 - 2005
OtherClass of 2000

Certifications & Licensure

FL State Medical License 2021 - Present
MI State Medical License 2009 - 2026
OH State Medical License 2004 - 2008
American Board of Internal Medicine Hospice and Palliative Medicine
American Board of Psychiatry and Neurology Neurology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM) Start of enrollment: 2009 Jun 01
Completed
Phase 3
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma Start of enrollment: 2015 Nov 30
Terminated
Phase 2, Phase 3
Terameprocol in Treating Patients With Recurrent High Grade Glioma Start of enrollment: 2018 May 03
Completed
Phase 1
Study of the Effect NT-I7 on CD4 Counts in Patients With High Grade Gliomas Start of enrollment: 2018 Oct 30
Terminated
Phase 1
Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer Start of enrollment: 2018 Jul 09
ACTIVE_NOT_RECRUITING
PHASE1
Microtubule-Targeted Agent BAL101553 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Start of enrollment: 2017 Dec 15
TERMINATED
PHASE1
MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas Start of enrollment: 2019 Sep 29
ACTIVE_NOT_RECRUITING
PHASE2
Join now to see all

Publications & Presentations

PubMed

2 citations
ReNeu: A Pivotal, Phase IIb Trial of Mirdametinib in Adults and Children With Symptomatic Neurofibromatosis Type 1-Associated Plexiform Neurofibroma.
Christopher L Moertel, Angela C Hirbe, Hans H Shuhaiber, Kevin Bielamowicz, Alpa Sidhu
Journal of Clinical Oncology. 2025-02-20
Levetiracetam and valproic acid in glioma: antiseizure and potential antineoplastic effects.
Bobak F Khalili, Tobias Walbert, Craig Horbinski, Karan Dixit, Kapil Gururangan
Future Oncology. 2025-02-01
Lisavanbulin (BAL101553), a novel microtubule inhibitor, plus radiation in patients with newly diagnosed, MGMT promoter unmethylated glioblastoma.
Matthias Holdhoff, Xiaobu Ye, Roy E Strowd, Burt Nabors, Tobias Walbert
Neuro-Oncology Advances. 2024-08-28

Press Mentions

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Looking to Fill Glioblastoma Multiforme Treatment Gap with Berubicin Drug ProductAugust 30th, 2022
Henry Ford Health Researchers Launch Clinical Trial Studying Therapy Aimed at Causing Brain Cancer Cells to Self-DestructJune 10th, 2023